Yap TA - Search Results

1

The changing therapeutic landscape of castration-resistant prostate cancer.

Yap TA, Zivi A, Omlin A, de Bono JS. Yap TA, et al. Nat Rev Clin Oncol. 2011 Aug 9;8(10):597-610. doi: 10.1038/nrclinonc.2011.117. Nat Rev Clin Oncol. 2011. PMID: 21826082 Review.

2

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18619560 Review.

3

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: yap ta. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.

4

Targeting the PI3K/AKT pathway for the treatment of prostate cancer.

Sarker D, Reid AH, Yap TA, de Bono JS. Sarker D, et al. Among authors: yap ta. Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638457 Free article. Review.

5

Envisioning the future of early anticancer drug development.

Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.

6

Cabazitaxel in metastatic castration-resistant prostate cancer.

Yap TA, Pezaro CJ, de Bono JS. Yap TA, et al. Expert Rev Anticancer Ther. 2012 Sep;12(9):1129-36. doi: 10.1586/era.12.88. Expert Rev Anticancer Ther. 2012. PMID: 23098113 Review.

7

Development of therapeutic combinations targeting major cancer signaling pathways.

Yap TA, Omlin A, de Bono JS. Yap TA, et al. J Clin Oncol. 2013 Apr 20;31(12):1592-605. doi: 10.1200/JCO.2011.37.6418. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509311 Review.

8

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Yap TA, et al. Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Nat Rev Drug Discov. 2016. PMID: 27444228 Review.

9

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA. O'Carrigan B, et al. Among authors: yap ta. Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318518 Free PMC article.

10

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page